Eng Hooi (Cheryl) Tan
BSc (Pharm), MPH, PhD
Postdoctoral Research Assistant in Pharmaco-epidemiological Methods
As a pharmacoepidemiologist, I apply methods to investigate the drug utilisation and comparative effectiveness and safety of medications using routinely collected healthcare data. I am currently involved in a study to assess the comparability of osteoporosis treatment groups via negative control outcomes analysis. I hope to support reliable evidence generation that translates into better patient care.
I completed my PhD at the National University of Singapore (NUS). My thesis explored the detection of drug-induced liver injury in electronic medical records. I obtained my Master of Public Health (MPH) from the University of Sydney and graduated from NUS with a BSc (Pharmacy) as an ASEAN scholar.
My working experience includes practicing as a pharmacist in a tertiary hospital and an oncology centre. While working on my PhD, I was also a research associate managing a randomised controlled trial evaluating the use of SMS reminders to improve medication adherence in women with breast cancer.
I joined NDORMS in June 2020.
Comparison of laboratory threshold criteria in drug-induced liver injury detection algorithms for use in pharmacovigilance.
Tan EH. et al, (2020), Pharmacoepidemiology and drug safety
Improving medication adherence with adjuvant aromatase inhibitor in women with breast cancer: A randomised controlled trial to evaluate the effect of short message service (SMS) reminder.
Tan EH. et al, (2020), Breast, 53, 77 - 84
Outcome-Based Critical Result Thresholds in the Adult Patient Population.
Tan EH. et al, (2019), Am j clin pathol, 152, 177 - 184
Relative criticalness of common laboratory tests for critical value reporting.
Yang Z. et al, (2019), J clin pathol, 72, 325 - 328
Improving medication adherence with adjuvant aromatase inhibitor in women with breast cancer: study protocol of a randomised controlled trial to evaluate the effect of short message service (SMS) reminder.
He Y. et al, (2018), Bmc cancer, 18